pH-Dependent Liquid-Liquid Phase Separation of Highly Supersaturated Solutions of Weakly Basic Drugs

Molecular Pharmaceutics

Volumn 12, Issue 7, 2015, Pages 2365-2377

  Indulkar, Anura S ^a   Box, Karl J ^b   Taylor, Robert ^b   Ruiz, Rebeca ^b   Taylor, Lynne S ^a  

^a PURDUE UNIVERSITY   (United States)

^b Sirius Analytical Instruments Ltd   (United Kingdom)

Author keywords

pH; solubility; supersaturation; weak base

Indexed keywords

ATAZANAVIR; CLOTRIMAZOLE; NICARDIPINE; ALKALI; SOLUTION AND SOLUBILITY; WATER;

ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; CRYSTALLIZATION; DRUG DOSAGE FORM; DRUG SOLUBILITY; DRUG STRUCTURE; FLUORESCENCE ANALYSIS; HENDERSON HASSELBALCH RELATION; IN VIVO STUDY; LIQUID LIQUID PHASE SEPARATION; PH; PHASE SEPARATION; PRECIPITATION; PRIORITY JOURNAL; THERMODYNAMICS; CHEMISTRY; PROCEDURES; SOLUBILITY; SOLUTION AND SOLUBILITY;

ALKALIES; CRYSTALLIZATION; HYDROGEN-ION CONCENTRATION; PHARMACEUTICAL SOLUTIONS; SOLUBILITY; WATER;

EID: 84936772811     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00056     Document Type: Article

References (54)

1. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2012, 64, 4-17
2. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2000, 44 (1) 235-249
3. Elworthy, P.; Patel, M. Demonstration of maximum solubilization in a polyoxyethylene alkyl ether series of non-ionic surfactants J. Pharm. Pharmacol. 1982, 34 (9) 543-546
4. Leuner, C.; Dressman, J. Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 2000, 50 (1) 47-60
5. Loftsson, T.; Brewster, M. E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization J. Pharm. Sci. 1996, 85 (10) 1017-1025
6. Vishweshwar, P.; McMahon, J. A.; Bis, J. A.; Zaworotko, M. J. Pharmaceutical co-crystals J. Pharm. Sci. 2006, 95 (3) 499-516
7. Berge, S. M.; Bighley, L. D.; Monkhouse, D. C. Pharmaceutical salts J. Pharm. Sci. 1977, 66 (1) 1-19
8. Miller, J. M.; Beig, A.; Carr, R. A.; Spence, J. K.; Dahan, A. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability Mol. Pharmaceutics 2012, 9 (7) 2009-2016
9. Veesler, S.; Lafferrère, L.; Garcia, E.; Hoff, C. Phase transitions in supersaturated drug solution Org. Process Res. Dev. 2003, 7 (6) 983-989
10. Bonnett, P. E.; Carpenter, K. J.; Dawson, S.; Davey, R. J. Solution crystallisation via a submerged liquid-liquid phase boundary: oiling out Chem. Commun. 2003, 6) 698-699
11. Zhao, H.; Xie, C.; Xu, Z.; Wang, Y.; Bian, L.; Chen, Z.; Hao, H. Solution Crystallization of Vanillin in the Presence of a Liquid-Liquid Phase Separation Ind. Eng. Chem. Res. 2012, 51 (45) 14646-14652
12. Veesler, S.; Revalor, E.; Bottini, O.; Hoff, C. Crystallization in the presence of a liquid-liquid phase separation Org. Process Res. Dev. 2006, 10 (4) 841-845
13. Lafferrère, L.; Hoff, C.; Veesler, S. In situ monitoring of the impact of liquid-liquid phase separation on drug crystallization by seeding Cryst. Growth Des. 2004, 4 (6) 1175-1180
14. Ilevbare, G. A.; Taylor, L. S. Liquid-Liquid Phase Separation in Highly Supersaturated Aqueous Solutions of Poorly Water-Soluble Drugs: Implications for Solubility Enhancing Formulations Cryst. Growth Des. 2013, 13 (4) 1497-1509
15. Almeida e Sousa, L.; Reutzel-Edens, S. M.; Stephenson, G. A.; Taylor, L. S. Assessment of the Amorphous "Solubility" of a Group of Diverse Drugs Using New Experimental and Theoretical Approaches Mol. Pharmaceutics 2015, 12 (2) 484-495
16. Lu, J.; Li, Y.-P.; Wang, J.; Ren, G.-B.; Rohani, S.; Ching, C.-B. Crystallization of an active pharmaceutical ingredient that oils out Sep. Purif. Technol. 2012, 96, 1-6
17. Tung, H.-H.; Paul, E. L.; Midler, M.; McCauley, J. A. Crystallization of Organic Compounds; John Wiley & Sons, Inc.: Hoboken, NJ, 2009; pp 101-116.
18. Sassano, M. F.; Doak, A. K.; Roth, B. L.; Shoichet, B. K. Colloidal aggregation causes inhibition of G protein-coupled receptors J. Med. Chem. 2013, 56 (6) 2406-2414
19. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening J. Med. Chem. 2002, 45 (8) 1712-1722
20. Frenkel, Y. V.; Clark, A. D.; Das, K.; Wang, Y.-H.; Lewi, P. J.; Janssen, P. A.; Arnold, E. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability J. Med. Chem. 2005, 48 (6) 1974-1983
21. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. A specific mechanism of nonspecific inhibition J. Med. Chem. 2003, 46 (20) 4265-4272
22. Alonzo, D. E.; Gao, Y.; Zhou, D.; Mo, H.; Zhang, G. G.; Taylor, L. S. Dissolution and precipitation behavior of amorphous solid dispersions J. Pharm. Sci. 2011, 100 (8) 3316-3331
23. Gao, P.; Rush, B. D.; Pfund, W. P.; Huang, T.; Bauer, J. M.; Morozowich, W.; Kuo, M. S.; Hageman, M. J. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability J. Pharm. Sci. 2003, 92 (12) 2386-2398
24. Huang, L. F.; Tong, W. Q. Impact of solid state properties on developability assessment of drug candidates Adv. Drug Delivery Rev. 2004, 56 (3) 321-334
25. Kerns, E. H.; Di, L. Drug-like Properties: Concepts, Structure Design and Methods, 1st ed.; Academic Press: San Diego, 2008; pp 48-55.
26. Kerns, E. H.; Di, L. Drug-like Properties: Concepts, Structure Design and Methods, 1st ed.; Academic Press: San Diego, 2008; pp 17-33.
27. Psachoulias, D.; Vertzoni, M.; Goumas, K.; Kalioras, V.; Beato, S.; Butler, J.; Reppas, C. Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults Pharm. Res. 2011, 28 (12) 3145-3158
28. Stahl, P. H.; Nakano, M. Pharmaceutical Aspects of the Drug Salt Form. In Handbook of pharmaceutical salts: properties, selection, and use; Stahl, P. H.; Wermuth, C. G., Eds.; Wiley-VCH: New York, 2002; pp 83-116.
29. Hsieh, Y. L.; Ilevbare, G. A.; Van Eerdenbrugh, B.; Box, K. J.; Sanchez-Felix, M. V.; Taylor, L. S. pH-Induced precipitation behavior of weakly basic compounds: determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties Pharm. Res. 2012, 29 (10) 2738-2753
30. Seidler, J.; McGovern, S. L.; Doman, T. N.; Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs J. Med. Chem. 2003, 46 (21) 4477-4486
31. Doak, A. K.; Wille, H.; Prusiner, S. B.; Shoichet, B. K. Colloid formation by drugs in simulated intestinal fluid J. Med. Chem. 2010, 53 (10) 4259-4265
32. Coan, K. E.; Maltby, D. A.; Burlingame, A. L.; Shoichet, B. K. Promiscuous aggregate-based inhibitors promote enzyme unfolding J. Med. Chem. 2009, 52 (7) 2067-2075
33. Feng, B. Y.; Toyama, B. H.; Wille, H.; Colby, D. W.; Collins, S. R.; May, B. C.; Prusiner, S. B.; Weissman, J.; Shoichet, B. K. Small-molecule aggregates inhibit amyloid polymerization Nat. Chem. Biol. 2008, 4 (3) 197-199
34. Coan, K. E.; Shoichet, B. K. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors J. Am. Chem. Soc. 2008, 130 (29) 9606-9612
35. Simon, N.; Dailly, E.; Jolliet, P.; Tillement, J.-P.; Urien, S. pH dependent binding of ligands to serum lipoproteins Pharm. Res. 1997, 14 (4) 527-532
36. Hancock, B. C.; Parks, M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 2000, 17 (4) 397-404
37. Murdande, S. B.; Pikal, M. J.; Shanker, R. M.; Bogner, R. H. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis J. Pharm. Sci. 2010, 99 (3) 1254-1264
38. Hoffman, J. D. Thermodynamic driving force in nucleation and growth processes J. Chem. Phys. 1958, 29 (5) 1192-1193
39. Kalyanasundaram, K.; Thomas, J. Environmental effects on vibronic band intensities in pyrene monomer fluorescence and their application in studies of micellar systems J. Am. Chem. Soc. 1977, 99 (7) 2039-2044
40. Greenspan, P.; Fowler, S. D. Spectrofluorometric studies of the lipid probe, nile red J. Lipid Res. 1985, 26 (7) 781-789
41. Xu, Z.; Singh, J.; Schwinden, M. D.; Zheng, B.; Kissick, T. P.; Patel, B.; Humora, M. J.; Quiroz, F.; Dong, L.; Hsieh, D.-M.; Heikes, J. E.; Pudipeddi, M.; Lindrud, M. D.; Srivastava, S. K.; Kronenthal, D. R.; Mueller, R. H. Process Research and Development for an Efficient Synthesis of the HIV Protease Inhibitor BMS-232632 Org. Process Res. Dev. 2002, 6 (3) 323-328
42. Kalyanasundaram, K.; Thomas, J. K. Solvent-dependent fluorescence of pyrene-3-carboxaldehyde and its applications in the estimation of polarity at micelle-water interfaces J. Phys. Chem. 1977, 81 (23) 2176-2180
43. Jackson, M. J.; Toth, S. J.; Kestur, U. S.; Huang, J.; Qian, F.; Hussain, M. A.; Simpson, G. J.; Taylor, L. S. Impact of polymers on the precipitation behavior of highly supersaturated aqueous danazol solutions Mol. Pharmaceutics 2014, 11 (9) 3027-3038
44. Andronis, V.; Yoshioka, M.; Zografi, G. Effects of sorbed water on the crystallization of indomethacin from the amorphous state J. Pharm. Sci. 1997, 86 (3) 346-351
45. Mullin, J. W. Crystallization, 4th ed.; Butterworth-Heinemann: Oxford, 2001; pp 86-132.
46. Gao, P.; Guyton, M. E.; Huang, T.; Bauer, J. M.; Stefanski, K. J.; Lu, Q. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations Drug Dev. Ind. Pharm. 2004, 30 (2) 221-229
47. Iervolino, M.; Raghavan, S.; Hadgraft, J. Membrane penetration enhancement of ibuprofen using supersaturation Int. J. Pharm. 2000, 198 (2) 229-238
48. Raina, S. A.; Zhang, G. G.; Alonzo, D. E.; Wu, J.; Zhu, D.; Catron, N. D.; Gao, Y.; Taylor, L. S. Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs J. Pharm. Sci. 2014, 103 (9) 2736-2748
49. FDA. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products: general considerations. US Department of Health and Human Services, Centre for Drug Evaluation and Research (CDER), 2003.
50. Mudie, D. M.; Murray, K.; Hoad, C. L.; Pritchard, S. E.; Garnett, M. C.; Amidon, G. L.; Gowland, P. A.; Spiller, R. C.; Amidon, G. E.; Marciani, L. Quantification of Gastrointestinal Liquid Volumes and Distribution Following a 240 mL Dose of Water in the Fasted State Mol. Pharmaceutics 2014) 11 (9) 3039-3047
51. Thelen, K.; Coboeken, K.; Willmann, S.; Burghaus, R.; Dressman, J. B.; Lippert, J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions J. Pharm. Sci. 2011, 100 (12) 5324-5345
52. Schiller, C.; Frohlich, C. P.; Giessmann, T.; Siegmund, W.; Monnikes, H.; Hosten, N.; Weitschies, W. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging Alimentary pharmacology & therapeutics 2005, 22 (10) 971-979
53. Carlert, S.; Palsson, A.; Hanisch, G.; von Corswant, C.; Nilsson, C.; Lindfors, L.; Lennernas, H.; Abrahamsson, B. Predicting intestinal precipitation - a case example for a basic BCS class II drug Pharm. Res. 2010, 27 (10) 2119-2130
54. Lui, C. Y.; Amidon, G. L.; Berardi, R. R.; Fleisher, D.; Youngberg, C.; Dressman, J. B. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans J. Pharm. Sci. 1986, 75 (3) 271-274